Cargando…
Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is the most common neurological condition in children. This pilot study evaluated the effects of high-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on the isolated plasma phospholipids and behavior in child...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971271/ https://www.ncbi.nlm.nih.gov/pubmed/17629918 http://dx.doi.org/10.1186/1475-2891-6-16 |
_version_ | 1782134874333773824 |
---|---|
author | Sorgi, Paul J Hallowell, Edward M Hutchins, Heather L Sears, Barry |
author_facet | Sorgi, Paul J Hallowell, Edward M Hutchins, Heather L Sears, Barry |
author_sort | Sorgi, Paul J |
collection | PubMed |
description | BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is the most common neurological condition in children. This pilot study evaluated the effects of high-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on the isolated plasma phospholipids and behavior in children with ADHD (primarily inattentive subtype and combined subtype). METHODS: Nine children were initially supplemented with 16.2 g EPA/DHA concentrates per day. The dosage was adjusted dependent on the ratio of arachidonic acid (AA) to EPA in the isolated plasma phospholipids at four weeks to reach a level normally found in the Japanese population. RESULTS: At the end of the eight-week study, supplementation resulted in significant increases in EPA and DHA, as well as a significant reduction in the AA:EPA ratio (20.78 ± 5.26 to 5.95 ± 7.35, p < 0.01). A psychiatrist (blind to supplement compliance or dosage modifications) reported significant improvements in behavior (inattention, hyperactivity, oppositional/defiant behavior, and conduct disorder). There was also a significant correlation between the reduction in the AA:EPA ratio and global severity of illness scores. CONCLUSION: The findings of this small pilot study suggest supplementation with high-dose EPA/DHA concentrates may improve behavior in children with ADHD. |
format | Text |
id | pubmed-1971271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-19712712007-09-08 Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder Sorgi, Paul J Hallowell, Edward M Hutchins, Heather L Sears, Barry Nutr J Research BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is the most common neurological condition in children. This pilot study evaluated the effects of high-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on the isolated plasma phospholipids and behavior in children with ADHD (primarily inattentive subtype and combined subtype). METHODS: Nine children were initially supplemented with 16.2 g EPA/DHA concentrates per day. The dosage was adjusted dependent on the ratio of arachidonic acid (AA) to EPA in the isolated plasma phospholipids at four weeks to reach a level normally found in the Japanese population. RESULTS: At the end of the eight-week study, supplementation resulted in significant increases in EPA and DHA, as well as a significant reduction in the AA:EPA ratio (20.78 ± 5.26 to 5.95 ± 7.35, p < 0.01). A psychiatrist (blind to supplement compliance or dosage modifications) reported significant improvements in behavior (inattention, hyperactivity, oppositional/defiant behavior, and conduct disorder). There was also a significant correlation between the reduction in the AA:EPA ratio and global severity of illness scores. CONCLUSION: The findings of this small pilot study suggest supplementation with high-dose EPA/DHA concentrates may improve behavior in children with ADHD. BioMed Central 2007-07-13 /pmc/articles/PMC1971271/ /pubmed/17629918 http://dx.doi.org/10.1186/1475-2891-6-16 Text en Copyright © 2007 Sorgi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Sorgi, Paul J Hallowell, Edward M Hutchins, Heather L Sears, Barry Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder |
title | Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder |
title_full | Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder |
title_fullStr | Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder |
title_full_unstemmed | Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder |
title_short | Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder |
title_sort | effects of an open-label pilot study with high-dose epa/dha concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971271/ https://www.ncbi.nlm.nih.gov/pubmed/17629918 http://dx.doi.org/10.1186/1475-2891-6-16 |
work_keys_str_mv | AT sorgipaulj effectsofanopenlabelpilotstudywithhighdoseepadhaconcentratesonplasmaphospholipidsandbehaviorinchildrenwithattentiondeficithyperactivitydisorder AT hallowelledwardm effectsofanopenlabelpilotstudywithhighdoseepadhaconcentratesonplasmaphospholipidsandbehaviorinchildrenwithattentiondeficithyperactivitydisorder AT hutchinsheatherl effectsofanopenlabelpilotstudywithhighdoseepadhaconcentratesonplasmaphospholipidsandbehaviorinchildrenwithattentiondeficithyperactivitydisorder AT searsbarry effectsofanopenlabelpilotstudywithhighdoseepadhaconcentratesonplasmaphospholipidsandbehaviorinchildrenwithattentiondeficithyperactivitydisorder |